Tellgen Corporation Share Price

Equities

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
13.73 CNY +0.88% Intraday chart for Tellgen Corporation +9.40% -22.21%

Financials

Sales 2022 716M 98.81M 8.24B Sales 2023 543M 74.91M 6.25B Capitalization 2.88B 397M 33.12B
Net income 2022 125M 17.25M 1.44B Net income 2023 89M 12.28M 1.02B EV / Sales 2022 3.98 x
Net cash position 2022 538M 74.2M 6.19B Net cash position 2023 483M 66.72M 5.56B EV / Sales 2023 4.41 x
P/E ratio 2022
27.1 x
P/E ratio 2023
32.2 x
Employees 710
Yield 2022
0.96%
Yield 2023
-
Free-Float 64.74%
More Fundamentals * Assessed data
Dynamic Chart
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024. CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares. CI
Tellgen Corporation authorizes a Buyback Plan. CI
Tellgen Corporation Announces Board Appointments CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tellgen Corporation, Shanghai Tellgen Diagnostic Technology Co., Ltd., Shanghai Maishi Jingwu Enterprise Management Partnership Enterprise (Limited Partnership), Yao Beier, Niu Zhengxiang and Zhan Hong agreed to acquire additional 5.71% stake in Shanghai Maishi Biotechnology Co., Ltd. from Wu Liang for CNY 1.4 million. CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023 CI
Tellgen Corporation Proposes Final Cash Dividend for 2022 CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021. CI
Tellgen Corporation's Equity Buyback announced on October 27, 2021, has expired with 1,062,840 shares, representing 0.65% for CNY 25.43 million. CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021. CI
More news
1 day+0.88%
1 week+9.40%
Current month-2.07%
1 month+1.03%
3 months-9.91%
6 months-16.08%
Current year-22.21%
More quotes
1 week
12.23
Extreme 12.23
13.82
1 month
11.86
Extreme 11.86
14.50
Current year
9.94
Extreme 9.94
18.02
1 year
9.94
Extreme 9.94
22.10
3 years
9.94
Extreme 9.94
50.25
5 years
9.94
Extreme 9.94
50.25
10 years
9.94
Extreme 9.94
50.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 06/03/06
Director/Board Member 45 01/09/01
Director/Board Member 42 01/09/01
Members of the board TitleAgeSince
Chief Executive Officer 54 06/03/06
Director/Board Member 61 14/19/14
Director/Board Member 42 01/09/01
More insiders
Date Price Change Volume
26/24/26 13.73 +0.88% 1,906,994
25/24/25 13.61 +2.64% 1,265,400
24/24/24 13.26 +2.95% 1,362,410
23/24/23 12.88 -0.62% 2,119,620
22/24/22 12.96 +3.27% 1,624,820

End-of-day quote Shenzhen S.E., April 26, 2024

More quotes
Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300642 Stock